Any content you receive is for information purposes only. Always conduct your own research. *Sponsored
Krypton Street Just Put (MTVA) On This Morning's Watchlist
—Wednesday, March 18, 2026.
Don't Miss The Next Breakout—Get Real-Time Alerts Sent Directly
To Your Phone. Up To 10X Faster Than Email.
Get (MTVA) On Your Radar While It's Still Early…
March 18, 2026
Coverage Initiated | See Why (MTVA) Just Hit This Morning's Early Watchlist
Dear Reader, Metabolic dysfunction is no longer sitting quietly in the background—it's becoming one of the main storylines in modern healthcare, and the markets tied to it are getting harder to ignore. Obesity therapeutics alone are projected to reach $67.16B by 2034, while cardiometabolic therapeutics are expected to climb from $68.4B in 2026 to more than $111B by 2035. Add in T2D therapeutics at $76.39B, broader diabetes therapeutics at $283.36B, and MASH therapeutics rising from $12.7B to $92.5B, and you can start to see why this space could gain much more attention . It doesn't stop there. Broader liver disease therapeutics are projected at $50.4B by 2034, inflammatory disease therapeutics at $293.4B by 2035, and even oncology enters the conversation as AI-modeling tools uncover shared inflammatory pathways across disease categories. It doesn't stop there. Broader liver disease therapeutics are projected at $50.4B by 2034, inflammatory disease therapeutics at $293.4B by 2035, and oncology at $697.59B by 2034. Meanwhile, AI-modeling tools are increasingly being used to identify shared inflammatory and cardiometabolic pathways that may extend beyond metabolic disease. That's where MetaVia Inc. (Nasdaq: MTVA) starts to get interesting: a clinical-stage biotech working at the intersection of obesity, liver disease, and cardiometabolic health, with AI-modeling results that support key inflammatory and cardiometabolic targets. That's part of why (MTVA) is topping our watchlist this morning—Wednesday, March 18, 2026.
But keep in mind, (MTVA) has less than 985K shares listed as available to the public. When companies have a razor-thin float like this, the potential exists for sharp moves if demand begins to shift. Right now, (MTVA) is sitting below $2 and appears to be flying under the radar of many screens. That's where it can help to look at what the chart is signaling in the near term—especially when sentiment has cooled. Technical readings show the RSI levels for (MTVA) have drifted into the 30-40 range for its 9-day, 14-day, 20-day, and 50-day time-frames—levels that some would describe as near "oversold territory", which could indicate a potential trend reversal is in the works. And when a company posts attention-grabbing clinical news in massive therapeutic categories, it's not unusual for analyst commentary to turn sharply more ambitious—sometimes very quickly. Recent Analyst Targets Suggest up to 3,900% Upside Potential
Several biotechnology analysts have begun to set targets that suggest (MTVA) is significantly overlooked relative to its recent clinical success: - Maxim Group: Analyst Jason McCarthy, Ph.D., has set a $8 target on MTVA, which suggests over 400% upside potential from its recent $1.50 range.
- Zacks SCR: Analyst David Bautz, Ph.D., has set a $60 target on MTVA, which suggests 3,900% upside potential from its recent range.
Taken together—large, fast-expanding therapeutic categories, recent clinical updates, and AI-enabled validation—(MTVA) is starting to look like one of those under-followed stories that can change quickly once more people connect the dots. Before we go any further, it helps to understand exactly what (MTVA) is building and why its approach is different. Engineering the Future of Metabolic Health
MetaVia Inc. (Nasdaq: MTVA) is a clinical-stage biotechnology company dedicated to transforming the treatment of cardiometabolic diseases. Formerly known as NeuroBo Pharmaceuticals, the company underwent a strategic rebranding to MetaVia to better align with its focus on the "Metabolic-Vascular" axis. Headquartered in Cambridge, MA, the company operates with a high-efficiency team and deep strategic ties to South Korean pharmaceutical giant Dong-A ST. What makes (MTVA) distinctive is its reliance on "dual-agonist" and "gut-pep-tide" engineering. Its lead candidate, DA-1726, is a novel oxyntomodulin (OXM) analogue that simultaneously activates the glucagon-like pep-tide-1 receptor (GLP1R) and the glucagon receptor (GCGR). While first-generation treatments often prioritize appetite suppression alone, DA-1726 aims to decrease food intake while increasing energy expenditure. This dual action mimics the body's natural gut hormones to potentially produce superior weight loss and metabolic improvement compared to selective GLP1R agonists. Simultaneously, the company is advancing vanoglipel (DA-1241), a novel G-protein-coupled receptor 119 (GPR119) agonist. This oral therapy promotes the release of endogenous GLP-1, GIP, and PYY. In clinical studies, vanoglipel has demonstrated the ability to reduce liver inflammation and fibrosis, providing a powerful one-two punch against MASH and Type 2 diabetes. Further reinforcing this program, (MTVA) recently announced an expansion of its global patent portfolio for vanoglipel, now covering 48 granted and pending patents across the U.S., Europe, Japan, China and other regions, with protection extending into 2035 unless extended further. The portfolio spans the compound, manufacturing processes, and therapeutic use across metabolic and liver diseases, strengthening the long-term positioning of its lead oral program. Best-in-Class Potential: The DA-1726 Breakthrough
In January 2026, (MTVA) released statistically significant results from its Phase 1b trial of DA-1726. The data from an 8-week cohort was nothing short of remarkable: patients achieved a 9.1% reduction in body weight (averaging 21.2 lbs) and a nearly 10 cm (3.8 inch) reduction in waist circumference. Furthermore, the trial showed a 23.7% reduction in liver stiffness (VCTE) in just 54 days. These results highlight the "glucagon effect"—where increasing energy expenditure targets visceral fat and liver health more aggressively than standard therapies. With no treatment-related discontinuations and a favorable safety profile, MTVA is setting a high bar for the next generation of weight-loss solutions. AI-Driven Precision: The Syntekabio Collaboration
The company's recent February 4, 2026 announcement confirmed that its collaboration with Syntekabio is yielding high-value insights. Using the DeepMatcher® AI platform, (MTVA) confirmed that vanoglipel strongly engages inflammatory and cardiometabolic target pathways. This validation is critical for the upcoming Phase 2b studies and potentially opens the door to oncology applications, as the AI identified strong anti-inflammatory signatures that could address cancer-related pathways. Financial Strength and Execution Runway
(MTVA) began 2026 by completing a $9.3M underwritten public offering, including the full exercise of the over-allotment option, adding capital intended for working capital and the continued clinical development of DA-1726. Readers who want the full structure and terms can review the company's announcement here. The management team, led by CEO Hyung Heon Kim and Chairman Andrew Koven—a former executive at Warner-Lambert and Merck—possesses the clinical and operational depth required to transition from a mid-stage biotech to a commercial-stage contender. 7 Reasons Why (MTVA) is Topping Our Watchlist This Morning
—Wednesday, March 18, 2026…
1. Low Float: With fewer than 985K shares listed as available to the public, (MTVA)'s small float could have the potential for big moves if demand begins to shift.
2. Massive Markets: (MTVA) is positioned across obesity ($67.16B), cardiometabolic ($111B+), T2D ($76.39B), MASH ($92.5B), and oncology ($697.59B) projections through 2034. 3. Analyst Targets: Multiple biotech analysts have issued targets on (MTVA) suggesting up to 3,900% upside from recent levels. 4. Technical Setup: RSI readings for (MTVA) sit in the 30–40 range across several timeframes, often associated with washed-out sentiment. 5. Clinical Data: Recent Phase 1b results from (MTVA) showed 9.1% body weight reduction and a 23.7% drop in liver stiffness in just 8 weeks. 6. AI Validation: An AI-modeling collaboration confirmed that (MTVA) aligns with key inflammatory and cardiometabolic targets. 7. Patent Strength: A newly expanded global portfolio gives (MTVA) 48 patents and protections extending into 2035 for its oral program. Pull Up (MTVA) While It's Still Early…
In the world of high-stakes biotechnology, data is the only currency that matters. MetaVia Inc. (Nasdaq: MTVA) has consistently delivered clinical results that not only meet but often exceed expectations for mid-stage candidates. The company's ability to target the most lucrative sectors in healthcare—obesity and liver disease—while leveraging AI-driven precision sets it apart from a sea of competitors. As MTVA advances toward its titration studies in late 2026 and further Phase 2b MASH milestones, the narrative of a transformation in cardiometabolic health is becoming impossible to ignore. For anyone closely monitoring the future of weight loss and metabolic restoration, (MTVA) is a symbol that could demand immediate attention as its clinical story continues to unfold. We have all eyes on (MTVA) this morning—Wednesday, March 18, 2026. Consider starting your own research on (MTVA) while it's still early. Also, keep a lookout for my next update, it could be coming before the bell rings. Sincerely, Alex Ramsay
Co-Founder / Managing Editor Krypton Street Newsletter
| 
